Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: In patients undergoing hemodialysis or hemofiltration will suffer from the injury of reactive oxidative species. Oxidative stress will affect cell membrane, protein, and DNA. It will damage the cell and result in organ dysfunction. We believe that in patients, who have acute hepatic failure, undergoing plasma exchange or Molecular Absorbent Recirculating System for bridge therapy will suffer from the injury of reactive oxidative species, too. It will damage the kidney, lung, cerebral cortex, and other organs. It may result in death before the recovery of liver function or undergoing liver transplantation.

Aims: 1. Investigate the severity of oxidative stress and risk factors of high oxidative stress in acute hepatic failure patient undergoing plasma exchange or Molecular Absorbent Recirculating System. 2. Investigate the microcirculation status and risk factors in acute hepatic failure patient undergoing plasma exchange or Molecular Absorbent Recirculating System. 3. Study the relationship between oxidative stress and microcirculation status. 4. Study the correlation between oxidative stress and prognosis. 5. Study the correlation between microcirculation status and prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of UC-MSC Transfusion for ACLF Patients

NCT04822922

Acute-On-Chronic Liver Failure

UNKNOWN PHASE2

The Plasma Diafiltration Therapy of Hepatic Failure

NCT03560414

Hepatic Failure Plasma Exchange

UNKNOWN NA

Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant

NCT01328132

Other Complications of Liver Transplant

UNKNOWN PHASE4

Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease

NCT02366845

Liver Disease

COMPLETED PHASE4

Hepatocyte Transplantation as a Life Support Bridge

NCT00282542

Fulminant Liver Failure

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Failure Critical Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

patient with hepatic failure undergoing liver support treatment in surgical intensive care unit

liver support treatment

Intervention Type OTHER

plasma exchange for liver support treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

liver support treatment

plasma exchange for liver support treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 years old
2. Patients with acute deterioration on Chronic liver failure, who required liver support treamtment
3. Patients with acute liver failure due to acute hepatitis, who reauired liver support treatment
4. Patients with acute liver dysfunction within 7 days after liver transplantation, who required liver support treatment

Exclusion Criteria

1. Age \> 70 years old
2. Cancer, not curable
3. Patients who had used of antioxidant therapy within 24 hours before study
4. Patients who had received hyperbaric oxygen therapy within 24 hours before study
5. Patients who had received peroxide treatment within 24 hours before study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No